Karyopharm Therapeutics Inc. (KPTI)

Market Cap	169.68M +117.5%
Revenue (ttm)	146.07M +0.6%
Net Income	-196.04M
EPS	-17.93
Shares Out	18.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	751,969
Open	9.64
Previous Close	9.40
Day's Range	9.14 - 9.82
52-Week Range	3.51 - 10.38
Beta	0.22
Analysts	Strong Buy
Price Target	22.17 (+139.68%)
Earnings Date	Feb 12, 2026

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2013
• Employees: 279
• Stock Exchange: NASDAQ
• Ticker Symbol: KPTI
• Website: https://www.karyopharm.com

Financial Performance

In 2025, Karyopharm Therapeutics's revenue was $146.07 million, an increase of 0.57% compared to the previous year's $145.24 million. Losses were -$196.04 million, 156.5% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for KPTI stock is "Strong Buy." The 12-month stock price target is $22.17, which is an increase of 139.68% from the latest price.

Price Target

$22.17

(139.68% upside)

Analyst Consensus: Strong Buy